SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-18-005937
Filing Date
2018-03-16
Accepted
2018-03-16 07:30:18
Documents
3
Period of Report
2018-03-16
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kalv-8k_20180316.htm 8-K 31468
2 EX-99.1 kalv-ex991_6.htm EX-99.1 387972
3 GRAPHIC g2018031605205750011709.jpg GRAPHIC 5519
  Complete submission text file 0001564590-18-005937.txt   428686
Mailing Address ONE KENDALL SQUARE BUILDING 200, STE. 2203 CAMBRIDGE MA 02139
Business Address ONE KENDALL SQUARE BUILDING 200, STE. 2203 CAMBRIDGE MA 02139 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

IRS No.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-36830 | Film No.: 18694196
SIC: 2834 Pharmaceutical Preparations